Gene Therapy for the Acute Respiratory Distress Syndrome

  • Phillip Factor
Part of the NATO ASI Series book series (NSSA, volume 297)


Gene therapy has been the focus of much attention and expectation in recent years. Many conditions have been identified as being likely targets for gene therapy, most of which are either heritable disorders or cancers. Recently acquired disorders, including acute lung diseases, have been identified as potential applications for gene therapy. Gene therapy has evolved from a concept to clinical application via phase I safety studies in humans. Due to current limitations of gene transfer technology little headway has been made in terms of true impact on human disease. Principal limitations of current technology have included lack of prolonged expression of transgenic proteins at physiologically relevant levels in an adequate number of target cells. Despite these stumbling blocks, optimism for gene therapy continues due to the belief that it will create new avenues for therapies that are not currently possible or imaginable. Gene therapy research continues to thrive due to its unrealized potential and with the hope that it will some day be common place therapy for a large number of conditions.


Nitric Oxide Gene Therapy Gene Transfer Acute Lung Injury Acute Respiratory Distress Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1).
    D.P. Carbone and D.N. Minna, In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus, J Natl Cancer Inst. 86:1437–1438 (1994).PubMedCrossRefGoogle Scholar
  2. 2).
    R.D. Alvarez and D.T. Curiel, A phase 1 study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HS V-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients, Hum Gene Ther. 8:597–613 (1997).PubMedCrossRefGoogle Scholar
  3. 3).
    D.T. Curiel, J.M. Pilewski, and S.M. Albelda, Gene therapy approaches for inherited and acquired lung diseases, Am J Respir Cell Mol Biol. 14:1–18 (1996).PubMedGoogle Scholar
  4. 4).
    F.D. Ledley, Nonviral gene therapy: the promise of genes as pharmaceutical products, Hum Gene Ther. 6:1129–1144 (1995).PubMedCrossRefGoogle Scholar
  5. 5).
    R.G. Hawley, F.H. Lieu, A.Z.C. Fong, and T.S. Hawley, Versatile retroviral vectors for potential use in gene therapy, Gene Ther 1:136–138 (1994).PubMedGoogle Scholar
  6. 6).
    R.G. Crystal, N.G. McElvaney, M.A. Rosenfeld. CS. Chu, A. Mastrangeli, J.G. Hay, S.L. Brody, H.A. Jaffe, N.T. Eissa, and C. Danel, Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cytic fibrosis, Nat Genet. 8:42–51 (1994).PubMedCrossRefGoogle Scholar
  7. 7).
    S.L. Brody, and R.G. Crystal. Adenovirus-mediated in vivo gene transfer, Ann NY Acad Sci. 716:90–101 (1994).PubMedCrossRefGoogle Scholar
  8. 8).
    B.C. Trapnell and M. Gorziglia, Gene therapy using adenoviral vectors, Curr opin Biotech. 5:617–625 (1994).PubMedCrossRefGoogle Scholar
  9. 9).
    M.P. Fink and D. Payen, The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18-20 March 1995, Int Care Med. 22:158–165 (1996).CrossRefGoogle Scholar
  10. 10).
    S.P. Janssens, K.D. Bloch, Z. Nong, R.D. Gerard, P. Zoldhelyi, and D. Collen, Adenoviral-mediated transfer of the human endothelial notric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats, J Clin Invest. 98:317–324 (1996).PubMedCrossRefGoogle Scholar
  11. 11).
    A. Hartog, D. Gommers, and B. Lachman, Role of surfactant in the pathophysiology of the acute respiratory distress syndrome(ARDS), Monaldi Arch Chest Dis. 50:327–377 (1995).Google Scholar
  12. 12).
    T.E. Nicholas, LR. Doyle, and A.D. Bersten, Surfactant replacement therapy in ARDS: white knight or noise in the system, Thorax 52:195–197 (1997).PubMedCrossRefGoogle Scholar
  13. 13).
    RJ. Korst, B. Bewig, and R.G. Crystal, In vitro and in vivo transfer and expression of human surfactant SP-A and SP-B associated protein cDNAs mediated by replication deficient, recombinant adenoviral vector. Hum Gene Ther. 6:277–87 (1995).PubMedCrossRefGoogle Scholar
  14. 14).
    S. Yei, C.J. Bachurski, T.E. Weaver, S.E. Wert, B.C. Trapnell, and J.A. Whitsett, Adenoviral-mediated gene transfer of human surfactant protein B to respiratory epithelial ells, Am J Resp Cell Mol Biol. 11:329–336 (1994).Google Scholar
  15. 15).
    Li, J., and R. Spragg, Adenovirus-mediated transfer of phosphocholine cytidylyltransferase gene to adult rat alveolar type II cells, Am J Resp Crit Care Med. 155:A213 (1997).Google Scholar
  16. 16).
    A.E. Canonico, K.L. Brigham, L.C. Carmichael, J.D. Plitman, G.A. King, T.R. Blackwell, and J.W. Christman, Plasmid-liposome transfer of the α1 antitrypsin gene to cystic fibrosis bronchial epithelial cells prevents elastase-induced cell detachment and cytokine release, Am J Resp Cell Mol Biol. 14:348–355 (1996).Google Scholar
  17. 17).
    A.E. Canonico, R.E. Parker, B.O. Meyrick, X. Gao, K. Lane, D. Cannon, T. Wilson, and K.L. Brigham, Alpha1 antitrypsin (AAT) gene therapy is superior to protein therapy in its protection against endotoxemia in a piglet in situ lung model. Am J Resp Crit Care Med. 155:A265 (1997).Google Scholar
  18. 18).
    C.A. Owen and E.J. Campbell, Proteinases, in: ARDS: Acute Respiratory Distress in Adults, T.W. Evans and C. Haslett, eds., Chapman and Hall, London (1996).Google Scholar
  19. 19).
    A.K. Tanswell and B.A. Freeman, Antioxidant therapy in critical care medicine, New Horizons. 3:330–341 (1995).PubMedGoogle Scholar
  20. 20).
    P. Prayssac, S.C. Erzurum, C. Danel, N.T. Eissa, R.G. Crystal, P. Herve, M. Mazmanian, and P. Lemarchand, Adenovirus-mediated transfer to the lungs of catalase and superoxide dismutase cDNAs prevents hyperoxia toxicity but not ischemia-reperfusion injury in rats, Am J Resp Crit Care Med. 155:A265, (1997).Google Scholar
  21. 21).
    W. Olivera, K. Ridge, L.D.H. Wood, and J.I. Sznajder, Active sodium transport and alveolar epithelial Na-K-ATPase increase during subacute hyperoxia in rats, Am J Physiol. 266:L577–L584 (1994).PubMedGoogle Scholar
  22. 22).
    P. Factor, C. Senne, K. Ridge, H.A. Jaffe, and J.I. Sznajder, Differential effects of adenoviral-mediated transfer of Na+,K+-ATPase subunit genes in lung epithelial cells, Chest 111(6 Suppl): 110S–l11S (1997).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1998

Authors and Affiliations

  • Phillip Factor
    • 1
  1. 1.Pulmonary and Critical Care Medicine, COLUMBIA/Michael Reese HospitalUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations